Maximal cytoreductive effort in epithelial ovarian cancer surgery

被引:110
|
作者
Shih, Karin K. [1 ]
Chi, Dennis S. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10065 USA
关键词
Ovarian cancer; Cytoreduction; PRIMARY PERITONEAL CANCER; SECONDARY CYTOREDUCTION; SURGICAL CYTOREDUCTION; RESIDUAL DISEASE; FALLOPIAN-TUBE; RECTOSIGMOID COLECTOMY; TERTIARY CYTOREDUCTION; 2ND-LOOK LAPAROTOMY; SELECTION CRITERIA; BOWEL RESECTION;
D O I
10.3802/jgo.2010.21.2.75
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The surgical management of advanced epithelial ovarian cancer involves cytoreduction, or removal of grossly-evident tumor. Residual disease after surgical cytoreduction of ovarian cancer has been shown to be strongly associated with survival. The goal of surgery is "optimal" surgical cytoreduction, which is generally defined as residual disease of 1 cm or less. However, the designation of "optimal" surgical cytoreduction has evolved to include maximal surgical effort and no gross residual disease. In order to achieve this, more aggressive surgical procedures such as rectosigmoidectomy, diaphragm peritonectomy, partial liver resection, and video-assisted thoracic surgery are reported and increasingly utilized in the surgical management of advanced ovarian cancer. The role of maximal surgical effort also extends to the recurrent setting where the goal of surgery should be complete cytoreduction. Patient selection is important in identifying appropriate candidates for surgical cytoreduction in the recurrent setting. The purpose of this article is to review the role of maximum surgical effort in primary and recurrent ovarian cancer.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 50 条
  • [21] Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma
    Tebes, Stephen J.
    Sayer, Robyn A.
    Palmer, James M.
    Tebes, Christine C.
    Martino, Martin A.
    Hoffman, Mitchel S.
    GYNECOLOGIC ONCOLOGY, 2007, 106 (03) : 482 - 487
  • [22] Does maximal effort cytoreductive surgery after 6-cycles of chemotherapy play a role in the management of advanced ovarian cancer?
    Cassar, Viktor
    Rundle, Stuart
    Rongali, Velangali Bhavya Swetha
    Korompelis, Porfyrios
    Ang, Christine
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2024, 310 (06) : 3057 - 3065
  • [23] Secondary Cytoreductive Surgery in the Management of Platinum-Sensitive Recurrent Epithelial Ovarian Cancer
    Park, Jeong-Yeol
    Eom, Jeong-Min
    Kim, Dae-Yeon
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    Nam, Joo-Hyun
    JOURNAL OF SURGICAL ONCOLOGY, 2010, 101 (05) : 418 - 424
  • [24] The feasibility and morbidity of distal pancreatectomy in extensive cytoreductive surgery for advanced epithelial ovarian cancer
    Yildirim Y.
    Sanci M.
    Archives of Gynecology and Obstetrics, 2005, 272 (1) : 31 - 34
  • [25] Towards a new standard in cytoreductive surgery for advanced ovarian cancer
    Querleu, D.
    Gladieff, L.
    Ferron, G.
    Rouge, P.
    BULLETIN DU CANCER, 2009, 96 (12) : 1175 - 1182
  • [26] Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis
    Bristow, Robert E.
    Puri, Isha
    Chi, Dennis S.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (01) : 265 - 274
  • [27] Role of cytoreductive surgery in recurrent ovarian cancer
    Harter, Philipp
    Hilpert, Felix
    Mahner, Sven
    Kommoss, Stefan
    Heitz, Florian
    du Bois, Andreas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (07) : 917 - 922
  • [28] Cytoreductive surgery for ovarian cancer
    Kecmanovic, DM
    Pavlov, MJ
    Kovacevic, PA
    Ceranic, MS
    Stamenkovic, AB
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (04): : 315 - 320
  • [29] Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma
    Scarabelli, C
    Gallo, A
    Carbone, A
    GYNECOLOGIC ONCOLOGY, 2001, 83 (03) : 504 - 512
  • [30] Splenectomy in cytoreductive surgery for advanced ovarian cancer
    Bilgin T.
    Özerkan K.
    Ozan H.
    Archives of Gynecology and Obstetrics, 2005, 271 (4) : 329 - 331